Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

BUY
$0.14 - $12.49 $350 - $31,274
2,504 Added 0.57%
443,531 $66,000
Q3 2022

Nov 14, 2022

SELL
$8.51 - $13.6 $38,303 - $61,213
-4,501 Reduced 1.01%
441,027 $4.62 Million
Q2 2022

Aug 11, 2022

BUY
$7.31 - $11.85 $131,755 - $213,584
18,024 Added 4.22%
445,528 $4.31 Million
Q3 2021

Nov 04, 2021

SELL
$3.56 - $4.64 $226,202 - $294,825
-63,540 Reduced 12.94%
427,504 $1.98 Million
Q2 2021

Aug 11, 2021

SELL
$3.95 - $5.41 $33,547 - $45,947
-8,493 Reduced 1.7%
491,044 $2.12 Million
Q1 2021

May 13, 2021

SELL
$4.52 - $7.8 $111,924 - $193,143
-24,762 Reduced 4.72%
499,537 $2.64 Million
Q4 2020

Feb 16, 2021

BUY
$4.37 - $9.46 $2.16 Million - $4.68 Million
494,307 Added 1648.13%
524,299 $3.7 Million
Q3 2020

Nov 12, 2020

BUY
$8.56 - $26.93 $114,549 - $360,377
13,382 Added 80.57%
29,992 $271,000
Q2 2020

Aug 13, 2020

BUY
$21.21 - $31.55 $181,960 - $270,667
8,579 Added 106.82%
16,610 $457,000
Q1 2020

May 14, 2020

SELL
$18.43 - $38.04 $355,588 - $733,943
-19,294 Reduced 70.61%
8,031 $177,000
Q4 2019

Feb 14, 2020

BUY
$29.6 - $43.71 $624,204 - $921,756
21,088 Added 338.11%
27,325 $1.03 Million
Q3 2019

Nov 14, 2019

SELL
$29.87 - $42.22 $279,732 - $395,390
-9,365 Reduced 60.02%
6,237 $191,000
Q2 2019

Aug 14, 2019

SELL
$31.16 - $39.46 $71,138 - $90,087
-2,283 Reduced 12.76%
15,602 $614,000
Q1 2019

May 15, 2019

BUY
$19.96 - $38.62 $167,304 - $323,712
8,382 Added 88.2%
17,885 $687,000
Q4 2018

Feb 14, 2019

SELL
$23.57 - $32.33 $399,487 - $547,961
-16,949 Reduced 64.07%
9,503 $223,000
Q3 2018

Dec 21, 2021

BUY
$22.5 - $39.35 $69,255 - $121,119
3,078 Added 13.17%
26,452 $808,000
Q3 2018

Nov 14, 2018

BUY
$22.5 - $39.35 $525,915 - $919,766
23,374 New
23,374 $713,000

Others Institutions Holding TCDA

About Tricida, Inc.


  • Ticker TCDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,668,900
  • Market Cap $557K
  • Description
  • Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...
More about TCDA
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.